Third-generation cephalosporins in the treatment of acute pneumococcal otitis media. An animal study.
There is concern that third-generation cephalosporins may not be effective in the treatment of acute otitis media due to Streptococcus pneumoniae. Using the chinchilla animal model, we compared two third-generation cephalosporins, cefixime (Suprax) and ceftibuten (investigational), with ampicillin and saline controls in an investigator-blinded, randomized trial. Whereas the saline controls performed worse than all other groups, no significant differences were detected among the three antibiotics regarding the time required to sterilize the middle ear cleft, or the prevalence of positive cultures after 10 days of therapy. The statistical power of the comparisons of cefixime and ceftibuten with ampicillin were 98% and 67%, respectively. The results of this in vivo animal study fail to support the contention that the two third-generation cephalosporins investigated are not effective in the treatment of pneumococcal acute otitis media. Caution is advised when extrapolating these results to the general clinical setting.
Rosenfeld
R M
RM
Pittsburgh Otitis Media Research Center, PA.
Doyle
W J
WJ
Swarts
J D
JD
Seroky
J
J
Pinero
B P
BP
D000158:Acoustic Impedance Tests; D000208:Acute Disease; D000667:Ampicillin / Q000627:therapeutic use; D000818:Animals; D020682:Cefixime; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000077722:Ceftibuten; D002511:Cephalosporins / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002682:Chinchilla; D004353:Drug Evaluation, Preclinical; D010034:Otitis Media with Effusion / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D011008:Pneumococcal Infections / Q000188:drug therapy*
D002511:Cephalosporins; D000667:Ampicillin; D020682:Cefixime; D000077722:Ceftibuten; D002439:Cefotaxime